Malaria [1]

Novartis has been committed to the fight against malaria for the past two decades. In 1999 we launched the first fixed-dose Artemisinin-based combination therapy (ACT) and in 2009 the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Today we are working on the development of the next generation of antimalarials.
Over the past 20 years, together with our partners, we have delivered more than 900 million treatments, including over 390 million pediatric treatments, without profit to malaria-endemic countries.

Follow us on social media at #MalariaFuture [2]

Read more about our malaria activities in our 2019 Novartis in Society Report [3].

**Working toward a malaria-free world**

Despite the tremendous progress made in combating malaria, one child still dies from the disease every two minutes. Novartis is committed to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% in 2030.

[Video of First child-friendly antimalarial 10 year anniversary]

**Working on the next generation of antimalarials**

“Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments,” said Vas Narasimhan, CEO of Novartis.

[Europe-Africa partnership spearheads development of next-generation antimalarial drug.]

Read the press release [4]

**Local insights and learnings are key to accelerating progress**

In 2018 and 2019, in order to bring voices from local malaria experts – from government, the research community and NGOs – in the global debate, we commissioned an opinion research in sub-Saharan and Central Africa, and in five countries in South and Southeast Asia on progress and challenges toward the 2030 malaria elimination goals. Despite differences, the MalaFA (Malaria Futures for Africa/Asia) reports identify common challenges such as the need for increased domestic financing; training new cohorts of healthcare workers in malaria
care; and continued investment in R&D to effectively fight insecticide and ACT resistance.

Learn more about the MalaFA reports [5].

How can digital help to fight malaria?

Bertrand Bodson, Chief Digital Officer at Novartis, shares his experience when he had malaria as a child. He highlights how digital can help to fight and eliminate malaria.

Video of How can digital help to fight malaria?

More on our malaria work

- Novartis malaria stories [6]
- Malaria resources [7]
- All malaria news [8]
- Follow us on social media at #MalariaFuture [2]
- Videos [9]

Novartis Social Business (NSB)

NSB supports global public health through novel sustainable business models. Our activities are rooted in local communities, where we work with partners to provide affordable, high-quality medicines against infectious and chronic diseases while strengthening healthcare capacity. Everything we do relies on our network of partners, who share our purpose.

Learn More [10]